NYSE:CAH - Cardinal Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $62.29
  • Forecasted Upside: 9.89 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$56.68
▲ +0.63 (1.12%)

This chart shows the closing price for CAH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardinal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CAH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CAH

Analyst Price Target is $62.29
▲ +9.89% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Cardinal Health in the last 3 months. The average price target is $62.29, with a high forecast of $65.00 and a low forecast of $57.00. The average price target represents a 9.89% upside from the last price of $56.68.

This chart shows the closing price for CAH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Cardinal Health. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$66.00 ➝ $64.00Low
5/10/2021Robert W. BairdDowngradeOutperform ➝ Neutral$66.00 ➝ $64.00Low
3/3/2021Morgan StanleyLower Price TargetEqual Weight$66.00 ➝ $64.00Low
1/8/2021Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
11/13/2020MizuhoBoost Price TargetNeutral$56.00 ➝ $59.00Low
11/9/2020Morgan StanleyBoost Price TargetEqual Weight$61.00 ➝ $66.00Low
11/6/2020Robert W. BairdBoost Price TargetOutperform$64.00 ➝ $70.00Low
11/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$61.00 ➝ $65.00Low
11/2/2020BarclaysUpgradeEqual Weight ➝ Overweight$57.00High
9/25/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$66.00 ➝ $61.00High
8/10/2020UBS GroupLower Price TargetBuy$65.00 ➝ $64.00Low
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$59.00 ➝ $61.00Low
7/21/2020Bank of AmericaBoost Price TargetBuy$61.00 ➝ $63.00Medium
7/20/2020GuggenheimUpgradeNeutral ➝ BuyHigh
6/15/2020Morgan StanleyBoost Price TargetEqual Weight$57.00 ➝ $59.00High
5/15/2020Bank of AmericaUpgradeBuyHigh
5/15/2020UBS GroupUpgradeNeutral ➝ Buy$48.00 ➝ $64.00High
5/12/2020MizuhoBoost Price TargetNeutral$50.00 ➝ $56.00Medium
5/12/2020Morgan StanleyBoost Price TargetEqual Weight$51.00 ➝ $57.00High
5/11/2020CfraLower Price TargetHold$61.00 ➝ $58.00Low
4/22/2020Credit Suisse GroupDowngradeHold$53.00Low
3/27/2020Morgan StanleyLower Price TargetEqual Weight$64.00 ➝ $51.00Low
3/20/2020Bank of AmericaUpgradeUnderperform ➝ Buy$57.00 ➝ $58.00High
2/12/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight$48.00 ➝ $64.00Low
2/7/2020MizuhoBoost Price TargetNeutral$52.00 ➝ $58.00Low
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$54.00 ➝ $68.00Low
2/6/2020CfraBoost Price TargetHold$56.00 ➝ $61.00High
1/19/2020BarclaysReiterated RatingHold$54.00Low
12/16/2019GuggenheimDowngradeBuy ➝ NeutralMedium
9/12/2019GuggenheimSet Price TargetBuy$55.00Low
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$50.00Low
9/6/2019Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $41.00N/A
8/27/2019ArgusDowngradeBuy ➝ HoldHigh
8/20/2019GuggenheimUpgradeNeutral ➝ Buy$50.00 ➝ $52.00Medium
4/17/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$51.00High
4/2/2019Wolfe ResearchInitiated CoverageUnderperformHigh
1/17/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$51.00Low
12/3/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$40.00 ➝ $50.00Low
11/16/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$55.00High
11/14/2018Jefferies Financial GroupReiterated RatingHold$61.00Low
11/9/2018Royal Bank of CanadaSet Price TargetHold$57.00Low
9/21/2018Royal Bank of CanadaSet Price TargetHold$60.00High
8/12/2018MizuhoReiterated RatingHold$53.00Low
8/7/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$51.00 ➝ $50.00Low
8/7/2018Royal Bank of CanadaReiterated RatingHold$56.00Medium
7/20/2018Robert W. BairdReiterated RatingHold$51.00Low
7/16/2018ArgusLower Price TargetBuy ➝ Buy$85.00 ➝ $75.00Low
7/3/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$55.00 ➝ $40.00Medium
5/7/2018MizuhoSet Price TargetHold$61.00Low
5/5/2018SVB LeerinkSet Price TargetBuy$65.00Low
5/4/2018Royal Bank of CanadaSet Price TargetHold$62.00High
5/4/2018Jefferies Financial GroupSet Price TargetHold$55.00High
4/24/2018Royal Bank of CanadaSet Price TargetHold$81.00Medium
4/24/2018SVB LeerinkUpgradeMarket Perform ➝ Outperform$75.00Low
4/16/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$74.00 ➝ $68.00Medium
4/2/2018ArgusUpgradeHold ➝ Buy$85.00High
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$74.00Low
2/27/2018Bank of AmericaInitiated CoverageUnderperform ➝ Underperform$69.00Low
2/9/2018Jefferies Financial GroupSet Price TargetHold$72.00Low
2/8/2018Royal Bank of CanadaSet Price TargetHold$83.00Low
1/24/2018MizuhoSet Price TargetHold$73.00Low
1/17/2018Robert W. BairdReiterated RatingHold$80.00Medium
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$67.00Medium
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$64.00High
11/20/2017Morgan StanleyDowngradeEqual Weight ➝ UnderweightN/A
11/15/2017ArgusDowngradeBuy ➝ HoldN/A
11/7/2017Jefferies Financial GroupLower Price TargetHold$77.00 ➝ $67.00N/A
10/24/2017MizuhoSet Price TargetHold$70.00N/A
10/12/2017Needham & Company LLCReiterated RatingHoldN/A
10/10/2017CowenUpgradeBuy$74.00N/A
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$72.00Low
9/17/2017Robert W. BairdReiterated RatingHold$73.00Low
9/10/2017Needham & Company LLCReiterated RatingHoldLow
8/29/2017Jefferies Financial GroupSet Price TargetHold$77.00Low
8/9/2017UBS GroupReiterated RatingNeutral$79.00 ➝ $76.00Medium
8/3/2017UBS GroupReiterated RatingNeutral$79.00 ➝ $76.00Low
8/3/2017CowenReiterated RatingMarket Perform$82.00 ➝ $77.00Low
8/3/2017Credit Suisse GroupLower Price TargetOutperform$87.00 ➝ $81.00Medium
7/27/2017Jefferies Financial GroupReiterated RatingHold$77.00Low
7/13/2017Credit Suisse GroupReiterated RatingOutperform$81.00 ➝ $87.00Low
7/4/2017Evercore ISIReiterated RatingOutperformN/A
5/17/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$77.00Medium
5/2/2017Evercore ISIBoost Price TargetOutperform$77.50 ➝ $78.00Medium
5/2/2017Credit Suisse GroupReiterated RatingBuy$81.00Medium
4/28/2017Tigress FinancialInitiated CoverageNeutral ➝ NeutralLow
4/25/2017CowenLower Price TargetMarket Perform$89.00 ➝ $82.00Low
4/22/2017BarclaysReiterated RatingOverweight$88.00 ➝ $82.00Low
4/21/2017SVB LeerinkSet Price TargetHold$72.00Low
4/19/2017William BlairDowngradeOutperform ➝ Market PerformLow
4/6/2017Evercore ISIUpgradeOutperformHigh
4/4/2017Needham & Company LLCInitiated CoverageHoldLow
2/8/2017SVB LeerinkSet Price TargetHold$81.00N/A
1/3/2017MizuhoDowngradeBuy ➝ Neutral$79.00N/A
12/21/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$75.00N/A
11/14/2016BarclaysSet Price TargetBuy$88.00N/A
11/2/2016SVB LeerinkReiterated RatingOutperform$95.00 ➝ $80.00N/A
10/28/2016Robert W. BairdDowngradeOutperform ➝ Neutral$92.00 ➝ $82.00N/A
10/10/2016Cleveland ResearchDowngradeBuy ➝ NeutralN/A
10/5/2016UBS GroupInitiated CoverageNeutral$82.00N/A
9/19/2016Bank of AmericaReiterated RatingHold$90.00N/A
9/16/2016The Goldman Sachs GroupDowngradeBuy ➝ Neutral$90.00 ➝ $83.00N/A
9/12/2016Morgan StanleyReiterated RatingHold$91.00N/A
8/30/2016Credit Suisse GroupReiterated RatingBuy$97.00N/A
8/4/2016Deutsche Bank AktiengesellschaftBoost Price TargetHold$83.00 ➝ $89.00N/A
8/3/2016SVB LeerinkReiterated RatingBuyN/A
8/3/2016CitigroupBoost Price TargetNeutral$87.00 ➝ $93.00N/A
7/6/2016The Goldman Sachs GroupReiterated RatingBuyN/A
(Data available from 6/21/2016 forward)
Cardinal Health logo
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, nutritional delivery, wound care, cardiovascular, and endovascular products; single-use surgical drapes, gowns and apparel, and fluid suction and collection systems; urology products; operating room supplies; and electrode products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Read More

Today's Range

Now: $56.68
Low: $56.14
High: $56.91

50 Day Range

MA: $58.41
Low: $55.56
High: $62.02

52 Week Range

Now: $56.68
Low: $44.65
High: $62.96

Volume

2,025,768 shs

Average Volume

2,118,759 shs

Market Capitalization

$16.45 billion

P/E Ratio

14.53

Dividend Yield

3.46%

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardinal Health?

The following Wall Street sell-side analysts have issued research reports on Cardinal Health in the last twelve months: Bank of America Co., Barclays PLC, Deutsche Bank Aktiengesellschaft, Guggenheim, Mizuho, Morgan Stanley, Robert W. Baird, TheStreet, UBS Group AG, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for CAH.

What is the current price target for Cardinal Health?

7 Wall Street analysts have set twelve-month price targets for Cardinal Health in the last year. Their average twelve-month price target is $62.29, suggesting a possible upside of 11.1%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting CAH will reach $65.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $57.00 for Cardinal Health in the next year.
View the latest price targets for CAH.

What is the current consensus analyst rating for Cardinal Health?

Cardinal Health currently has 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CAH will outperform the market and that investors should add to their positions of Cardinal Health.
View the latest ratings for CAH.

What other companies compete with Cardinal Health?

Other companies that are similar to Cardinal Health include McKesson, AmerisourceBergen, Henry Schein, Patterson Companies and Owens & Minor.

How do I contact Cardinal Health's investor relations team?

Cardinal Health's physical mailing address is 7000 CARDINAL PLACE, DUBLIN OH, 43017. The company's listed phone number is 614-757-5000 and its investor relations email address is [email protected] The official website for Cardinal Health is www.cardinalhealth.com.